← Oncology Approval Tracker

FDA DECISION ·

Tivdak

tisotumab vedotin-tftv · Seagen

Accelerated approvalNew therapyCervical cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Apr 29, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with recurrent or metastatic cervical cancer whose disease progressed during or after chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The initial accelerated action introduced a tissue factor-directed antibody-drug conjugate. FDA later granted traditional approval on April 29, 2024.

What research teams should watch

Coordinate eye examinations and preventive eye care with infusions and document prior chemotherapy progression.

PRIMARY RECORDS

Sources